Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.55 |
| ▸ | RAB9A | P51151 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301542 | 0.74 | NPC1 (0.58) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3685297 | 0.73 | ADRA2A (0.45) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30561047 | 0.73 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30634854 | 0.73 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL172216 | 0.73 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8688464 | 0.72 | FGFR1 (0.56) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| Water SCHEMBL9817804 | 0.71 | NPC1 (0.95) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5324075 | 0.71 | NPC1 (0.50) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3835162 | 0.70 | RAB9A (0.50) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7140034 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9490437-B2 | Organometallic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-11-08 | — | — | US | claimed |
| EP-0944582-B1 | KETOBENZAMIDES AS CALPAIN INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2003-07-02 | — | — | EP | claimed |
| EP-0559891-B1 | THIENODIAZEPINE COMPOUND AND ITS USE | YOSHITOMI PHARMACEUTICAL (JP) | 2000-01-12 | — | — | EP | claimed |
| US-5795893-A | Fibrinogen receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-18 | — | — | US | claimed |
| US-5599810-A | ADMINISTERING IN TREATMENT OF BENIGN PROSTATIC HYPERTROPHY, PERIPHERAL VASCULAR DISEASE AND CONGESTIVE HEART FAILURE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-04 | — | — | US | claimed |
| EP-0684949-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-06 | — | — | EP | claimed |
| EP-0684949-A4 | CHEMICAL COMPOUNDS. | SMITHKLINE BEECHAM CORP (US) | 1995-10-13 | — | — | EP | claimed |
| WO-1994019354-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-09-01 | — | — | WO | claimed |
| CN-117062455-A | Organic light emitting device and electronic apparatus including the same | 三星显示有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111740024-B | organic light emitting device | 三星显示有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-2257171-B1 | TETRAHYDRO-1H-PYRROLO-FUSED PYRIDONES | MERCK SHARP & DOHME (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20100197564-A1 | DIARYL MORPHOLINES AS CB1 MODULATORS | SCHERING CORPORATION | 2010-08-05 | — | — | US | disclosed |
| WO-2008130616-A2 | DIARYL MORPHOLINES AS CB1 MODULATORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1628971-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | disclosed |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2004101555-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-0944582-B1 | KETOBENZAMIDES AS CALPAIN INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197564-A1 | DIARYL MORPHOLINES AS CB1 MODULATORS | CNR1, CNR2, GPR119 | NPC1 292/4885RAB9A 2057/4885ALDH1A1 2136/4885 |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | NPC1 1345/4885RAB9A 1129/4885ALDH1A1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.